Quality of life and adherence to treatment in patients with benign prostatic hyperplasia treated with tamsulosin 0.4 mg/dutasteride 0.5 mg for 12 weeks.
DOI:
https://doi.org/10.29166/rfcmq.v48i2.4435Keywords:
prostatic hyperplasia, treatment adherence and compliance, quality of LifeAbstract
Introduction
Benign prostatic hyperplasia is defined as benign growth of the prostate, accompanied by lower urinary tract symptoms. This is a public health problem in the elderly population. Treatment can be clinical or surgical.
Objective
To assess the quality of life, satisfaction and adherence to treatment of patients with Benign Prostatic Hyperplasia treated with the tamsulosin/dutasteride combination for 12 weeks.
Material and methods
A single-cohort study was designed to evaluate the quality of life, satisfaction, and adherence to treatment of patients diagnosed with benign prostatic hyperplasia treated with the combination of tamsulosin 0.4 mg/dutasteride 0.5 mg for 12 weeks. A total of 103 patients were evaluated using a Patient Reported Outcomes survey, the International Prostate Symptom Score (IPSS), and the EQ-5 questionnaire.
Results
The average age of the participants was 65 ± 7 years, 50% of the patients were between 59 and 71 years old. At baseline, 35.9% (n=37) of the cases reported moderate symptoms, while 64.1% (n=58) reported severe symptoms. At the end of treatment, 98.1% (n=101) of patients scored moderate symptoms and 1.9% (n=2) severe symptoms. When comparing the means of the initial IPSS score with the final one, a decrease in the severity of symptoms was reported (p<0.01), with a reduction of 11.95 being observed. The improvement in the patient's self-perceived global health status at baseline reported an average of 7.1 ± 1.9; and at the end of treatment the average was 8.6 ± 0.9. (p < 0.01)
Downloads
Metrics
References
- Zambrano N, Palma C. Management of Benign Prostatic Hyperplasia and erectile dysfunction by the general physician, Rev. Med. Clin. CONDES. [Publicación periódica en línea] 2018. [Citado: 2022 febrero 14]; 29(2): [180-192 pp]. DOI: 10.1016/j.rmclc.2018.01.003.
- Madersbachera S, Sampsonc S, Culig Z. Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review, Gerontology. [Publicación periódica en línea] 2019. [Citado: 2022 febrero 14]; 65(5): [458–464 pp]. DOI: 10.1159/000496289.
- Bortnick E, Brown C, Simma-Chiang V, Kaplan SA. Modern best practice in the management of benign prostatic hyperplasia in the elderly. Ther Adv Urol. [Publicación periódica en línea] 2020. [Citado: 2022 febrero 14]; May 27; 12: [1-11 pp]. DOI: 10.1177/1756287220929486.
- Robert G, De La Taille A, Descazeaud A. Données épidémiologiques en rapport avec la prise en charge de l’HBP [Epidemiology of benign prostatic hyperplasia]. Prog Urol. [Publicación periódica en línea] 2018. [Citado: 2022 febrero 15];28(15): [803-812 pp]. DOI: 10.1016/j.purol.2018.08.005.
- Tsunemori H, Sugimoto M. Effects of inflammatory prostatitis on the development and progression of benign prostatic hyperplasia: A literature review. Int J Urol. [Publicación periódica en línea] 2021. [Citado: 2022 febrero 15]; Nov;28(11): [1086-1092 pp]. DOI: 10.1111/iju.14644.
- Devlin CM, Simms MS, Maitland NJ. Benign prostatic hyperplasia - what do we know? BJU Int. [Publicación periódica en línea] 2021. [Citado: 2022 febrero 15]; Apr;127(4): [389-399 pp]. DOI: 10.1111/bju.15229.
- Presicce F, De Nunzio C, Tubaro A. Clinical Implications for the Early Treatment of Benign Prostatic Enlargement (BPE): a Systematic Review. Curr Urol Rep. [Publicación periódica en línea] 2018; [Citado: 2022 febrero 16]; Jul 9;19(9): [70 pp]. DOI: 10.1007/s11934-018-0823-y.
- Albisinni S, Aoun F, Roumeguère T, Porpiglia F, Tubaro A, DE Nunzio C. New treatment strategies for benign prostatic hyperplasia in the frail elderly population: a systematic review. Minerva Urol Nefrol. [Publicación periódica en línea] 2017; [Citado: 2022 febrero 17] Apr;69(2): [119-132 pp]. DOI: 10.23736/S0393-2249.16.02743-0.
- Instituto Guatemalteco de Seguridad Social (IGSS) Subgerencia de Prestaciones en Salud Comisión de Elaboración de Guías de Práctica Clínica Basadas en Evidencia (GPC-BE) GPC-BE 74 “Manejo de la Hipertrofia Prostática Benigna” [Publicación periódica en línea] Edición 2016 [Citado: 2022 febrero 17]; [85 pp]. Disponible en: http: GPC-BE No. 74 Manejo de la Hipertrofia Prostatica Benigna.pdf (igssgt.org)
- Cai T, Cui Y, Yu S, Li Q, Zhou Z, Gao Z. Comparison of Serenoa repens With Tamsulosin in the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. Am J Mens Health. [Publicación periódica en línea] 2020; [Citado: 2022 febrero 18] Mar-Apr;14(2): DOI: 10.1177/1557988320905407.
- Csikós E, Horváth A, Ács K, Papp N, Balázs VL, Dolenc MS, Kenda M, Kočevar Glavač N, Nagy M, Protti M, Mercolini L, Horváth G, Farkas Á, On Behalf Of The Oemonom. Treatment of Benign Prostatic Hyperplasia by Natural Drugs. Molecules. [Publicación periódica en línea] 2021; [Citado: 2022 febrero 18] Nov 25;26(23): [7141 pp]. DOI: 10.3390/molecules26237141.
- Karavitakis M, Kyriazis I, Omar MI, Gravas S, Cornu JN, Drake MJ, Gacci M, Gratzke C, Herrmann TRW, Madersbacher S, Rieken M, Speakman MJ, Tikkinen KAO, Yuan Y, Mamoulakis C. Management of Urinary Retention in Patients with Benign Prostatic Obstruction: A Systematic Review and Meta-analysis. Eur Urol. [Publicación periódica en línea] 2019; [Citado: 2022 febrero 18] May;75(5): [788-798 pp]. DOI: 10.1016/j.eururo.2019.01.046.
- Zerafatjou N, Amirzargar M, Biglarkhani M, Shobeirian F, Zoghi G. Pumpkin seed oil (Cucurbita pepo) versus tamsulosin for benign prostatic hyperplasia symptom relief: a single-blind randomized clinical trial. BMC Urol. [Publicación periódica en línea] 2021; [Citado: 2022 febrero 18] Oct 19;21(1): [147 pp]. DOI: 10.1186/s12894-021-00910-8.
- Jun JEJ, Kinkade A, Tung ACH, Tejani AM. 5α-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. Can J Hosp Pharm. [Publicación periódica en línea] 2017; [Citado: 2022 febrero 19] Mar-Apr;70(2): [113-119 pp]. DOI: 10.4212/cjhp.v70i2.1643.
- López-Ramos H, Medina-Rico M, Bastidas D, Lara B. Tratamiento farmacológico de la hiperplasia prostática benigna. Revisión de la bibliografía. Rev Mex Urol. [Publicación periódica en línea] 2018; [Citado: 2022 febrero 19] julio-agosto;78(4): [321-334 pp]. DOI: https://doi.org/10.24245/revmexurol.v78i4.2093
- Ma C, Zhang J, Cai Z, Li H. To evaluate the efficacy and safety of different kinds of PDE5-Is with tamsulosin as a medical therapy for LUTS secondary to benign prostatic hyperplasia: A protocol for systematic review and meta analysis. Medicine (Baltimore). [Publicación periódica en línea] 2020; [Citado: 2022 febrero 19] Jan;99(3):e18712. DOI: 10.1097/MD.0000000000018712.
- Kim SJ, Shin IS, Eun SJ, Whangbo TK, Kim JW, Cho YS, Kim JC. Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients. Int Neurourol J. [Publicación periódica en línea] 2017; [Citado: 2022 febrero 20] Mar 24;21(1): [29-37 pp]. DOI: 10.5213/inj.1734826.413.
- Zhou Z, Cui Y, Wu J, Ding R, Cai T, Gao Z. Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasterida compared with tamsulosin monotherapy in treating benign prostatic hyperplasia. BMC Urol. [Publicación periódica en línea] 2019; [Citado: 2022 febrero 20] Mar 11;19(1): [17 pp]. DOI: 10.1186/s12894-019-0446-8.
Haque N, Masumori N, Sakamoto S, Ye Z, Yoon SJ, Kuo HC, Brotherton B, Wilson T, Muganurmath C, McLaughlin M, Manyak M. Superiority of dutasterida 0.5 mg and tamsulosin 0.2 mg for the treatment of moderate-to-severe benign prostatic hyperplasia in Asian men. Int J Urol. [Publicación periódica en línea] 2018; [Citado: 2022 febrero 20] Nov;25(11): [944-951 pp]. DOI: 10.1111/iju.13785.
- Guevara-Cuellar CA, Parody-Rúa E, Garcia-Perdomo HA, Arenas-Duque A. Cost-Effectiveness of Combination Therapy Versus Monotherapy in Benign Prostatic Hyperplasia: A Colombian Experience. Value Health Reg Issues. [Publicación periódica en línea] 2018; [Citado: 2022 febrero 20] Dec;17: [174-182 pp]. DOI: 10.1016/j.vhri.2018.09.004.
- Kang D, Hu C, Fu Y, Wang D. Combination of α-blocker and 5α-reductase inhibitor for treatment of benign prostatic hyperplasia. Clin Invest Med. [Publicación periódica en línea] 2017; [Citado: 2022 febrero 20] Oct 19;40(5): [E200-E210]. DOI: 10.25011/cim.v40i5.28625.
- Lulic Z, Son H, Yoo SB, Cunnington M, Kapse P, Miller D, Cortes V, Park S, Bhak RH, Duh MS. Free combination of dutasterida plus tamsulosin for the treatment of benign prostatic hyperplasia in South Korea: analysis of drug utilization and adverse events using the National Health Insurance Review and Assessment Service database. BMC Urol. [Publicación periódica en línea] 2021; [Citado: 2022 febrero 20] Dec 21;21(1): [178 pp]. DOI: 10.1186/s12894-021-00941-1.
- D'Agate S, Wilson T, Adalig B, Manyak M, Palacios-Moreno JM, Chavan C, Oelke M, Roehrborn C, Della Pasqua O. Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH. World J Urol. [Publicación periódica en línea] 2020; [Citado: 2022 febrero 20] Feb;38(2): [463-472 pp]. DOI: 10.1007/s00345-019-02783-x.
- D'Agate S, Chavan C, Manyak M, Palacios-Moreno JM, Oelke M, Michel MC, Roehrborn CG, Della Pasqua O. Impact of early vs. delayed initiation of dutasterida/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression. World J Urol. [Publicación periódica en línea] 2021; [Citado: 2022 febrero 20] Jul;39(7): [2635-2643 pp]. DOI: 10.1007/s00345-020-03517-0
- El-Adawy MS, Abdelaziz AY, Salem A, Ela WA, Moussa AS, Ibrahim R, Zanaty F, Abdelhamid MH, Aldaqadossi H, Ragheb AM, Shaker HA, Kotb S. Relation of baseline prostate volume to improvement of lower urinary tract symptoms due to tamsulosin monotherapy in benign prostatic hyperplasia: An exploratory, multicenter, prospective study. Urol Ann. [Publicación periódica en línea] 2020; [Citado: 2022 febrero 20] Jul-Sep;12(3): [271-275 pp]. DOI: 10.4103/UA.UA_91_19.
- Calogero AE, Burgio G, Condorelli RA, Cannarella R, La Vignera S. Epidemiology and risk factors of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction. Aging Male. [Publicación periódica en línea] 2019; [Citado: 2022 noviembre 22] Mar;22(1): [12-19 pp]. DOI: 10.1080/13685538.2018.1434772.
- Drake MJ, Bowditch S, Arbe E, Hakimi Z, Guelfucci F, Amri I, Nazir J. A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands. BMC Urol. [Publicación periódica en línea] 2017; [Citado: 2022 noviembre 22] May 22;17(1): [36 pp]. DOI: 10.1186/s12894-017-0226-2.
- Rosen RC, Roehrborn CG, Manyak MJ, Palacios-Moreno JM, Wilson TH, Lulic Z, Giuliano F. Evaluation of the impact of dutasteride/tamsulosin combination therapy on libido in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH): A post hoc analysis of a prospective randomised placebo-controlled study. Int J Clin Pract. [Publicación periódica en línea] 2019; [Citado: 2022 noviembre 23] Sep;73(9): [1 -9 pp]. DOI: 10.1111/ijcp.13282.
- Eisen C, Lulic Z, Palacios-Moreno JM, Adalig B, Hennig M, Cortes V, Gilg F, Kostev K. Persistence and adherence to dutasteride/tamsulosin fixed-dose versus free-combination alpha blocker/5ARI therapy in patients with benign prostate hyperplasia in Germany . Int J Clin Pharmacol Ther. [Publicación periódica en línea] 2020; [Citado: 2022 noviembre 26] Jan;58(1): [37 - 49 pp]. DOI: 10.5414/CP203549.
- Moncada I, Krishnappa P. Re: A Prospective Randomised Placebo-controlled Study of the Impact of Dutasteride/Tamsulosin Combination Therapy on Sexual Function Domains in Sexually Active Men with Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH). Eur Urol. [Publicación periódica en línea] 2019; [Citado: 2022 noviembre 26] Feb;75(2): [344 - 345 pp]. DOI: 10.1016/j.eururo.2018.10.034
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Sandro Patricio Romero Proaño
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
